Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GJB2 | P29033 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16678933 | 1.00 | SLC2A1 (0.56) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL16678919 | 0.98 | SLC2A1 (0.58) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL7696481 | 0.95 | GBA1 (0.56) | SLC2A1GBA1MAPK1GJB2LGALS8 | |
| SCHEMBL16395631 | 0.95 | GBA1 (0.56) | SLC2A1GBA1MAPK1GJB2LGALS8 | |
| SCHEMBL3502893 | 0.95 | GBA1 (0.56) | SLC2A1GBA1MAPK1GJB2LGALS8 | |
| SCHEMBL11222662 | 0.95 | SLC2A1 (0.54) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL10388278 | 0.95 | SLC2A1 (0.54) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL16678877 | 0.95 | SLC2A1 (0.54) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL23646744 | 0.94 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL6565021 | 0.94 | GBA1 (0.59) | SLC2A1GBA1MAPK1GJB2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| US-8202844-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | SLC2A1 3044/4885GBA1 3968/4885MAPK1 3776/4885 |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | SLC2A1 3044/4885GBA1 3968/4885MAPK1 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.